AR105711A1 - Compuestos de hidroxitriazina y sus usos farmacéuticos - Google Patents
Compuestos de hidroxitriazina y sus usos farmacéuticosInfo
- Publication number
- AR105711A1 AR105711A1 ARP160102503A ARP160102503A AR105711A1 AR 105711 A1 AR105711 A1 AR 105711A1 AR P160102503 A ARP160102503 A AR P160102503A AR P160102503 A ARP160102503 A AR P160102503A AR 105711 A1 AR105711 A1 AR 105711A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- formula
- hydrogen
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente proporciona un compuesto que tiene una actividad inhibidora de mPGES-1 y es de utilidad para la prevención o el tratamiento de dolor, reumatismo, osteoartritis, fiebre, enfermedad de Alzheimer, esclerosis múltiple, arteriosclerosis, glaucoma, hipertensión ocular, enfermedad retinal isquémica, esclerodermia sistémica y/o cáncer incluyendo cáncer colorrectal. También se refiere a un compuesto de la fórmula (1), (2) ó (3) o una de sus sales farmacéuticamente aceptables. Reivindicación 1: Un compuesto de la fórmula (1), (2) ó (3) o una de sus sales farmacéuticamente aceptables, caracterizado porque R¹ es (I) la fórmula (4) en donde R¹ᵃ es alquilo C₁₋₄, R¹ᵇ es alquilo C₁₋₄ o trifluorometilo y R¹ᶜ es (a) alquilo C₁₋₄, (b) fluoroalquilo C₁₋₄, (c) alcoxi C₁₋₄ o (d) alcoxi C₁₋₄-alquilo C₁₋₄ o (II) la fórmula (5) en donde n es 1, 2, 3, 4 ó 5 y R¹ᵈ es (a) fluoro, (b) alquilo C₁₋₄, (c) fluoroalquilo C₁₋₄, (d) alcoxi C₁₋₄ o (e) alcoxi C₁₋₄-alquilo C₁₋₄; R² es hidrógeno o alquilo C₁₋₄; R³ es (I) hidrógeno, (II) halógeno, (III) alquilo C₁₋₄ o (IV) alcoxi C₁₋₄; R⁴ es (I) la fórmula (6), en donde R⁴ᵃ es hidrógeno, alquilo C₁₋₄ o alcoxi C₁₋₄ o (II) la fórmula (7); R⁵ es alquilo C₁₋₆; R⁶ es (I) alquilo C₁₋₆, (II) cicloalquilo C₃₋₅ o (III) alcoxi C₁₋₄-alquilo C₁₋₄, y X es CH₂ u O, siempre que, cuando R² en la fórmula (1) es alquilo C₁₋₄, entonces R³ sea hidrógeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015160284 | 2015-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105711A1 true AR105711A1 (es) | 2017-11-01 |
Family
ID=58052084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102503A AR105711A1 (es) | 2015-08-17 | 2016-08-16 | Compuestos de hidroxitriazina y sus usos farmacéuticos |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20170057943A1 (es) |
| EP (2) | EP4046991A1 (es) |
| JP (4) | JP2017039714A (es) |
| KR (1) | KR20180037270A (es) |
| CN (1) | CN108137515B (es) |
| AR (1) | AR105711A1 (es) |
| AU (1) | AU2016309337B2 (es) |
| BR (1) | BR112018001809A2 (es) |
| CA (1) | CA2992410A1 (es) |
| CL (1) | CL2018000430A1 (es) |
| CO (1) | CO2018002516A2 (es) |
| IL (1) | IL257559B (es) |
| MX (1) | MX2018002044A (es) |
| PE (1) | PE20180951A1 (es) |
| PH (1) | PH12018500181A1 (es) |
| SG (1) | SG11201800698VA (es) |
| TW (1) | TWI704139B (es) |
| WO (1) | WO2017030115A1 (es) |
| ZA (1) | ZA201801134B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20180951A1 (es) * | 2015-08-17 | 2018-06-11 | Japan Tobacco Inc | Compuestos de hidroxitriazina y usos medicos de los mismos |
| ES2902127T3 (es) * | 2015-10-29 | 2022-03-25 | Aska Pharm Co Ltd | Derivado de pirimidina |
| RU2648181C1 (ru) * | 2017-05-25 | 2018-03-22 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лечения нейроретинопатии вследствие тяжелой преэклампсии |
| EP3645527A1 (de) * | 2017-06-26 | 2020-05-06 | Merck Patent GmbH | Verfahren zur herstellung substituierter stickstoffhaltiger heterocyclen |
| TW202409037A (zh) * | 2022-07-06 | 2024-03-01 | 日商Ａｓｋａ製藥股份有限公司 | 嘧啶衍生物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2138488A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
| GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| CN101747282A (zh) * | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
| CA2811154C (en) * | 2009-09-23 | 2019-01-08 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
| AR086254A1 (es) | 2011-05-26 | 2013-11-27 | Lilly Co Eli | Derivados de imidazol utiles para el tratamiento de artritis |
| TWI568722B (zh) * | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| WO2015059618A1 (en) * | 2013-10-22 | 2015-04-30 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS |
| TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| PE20180951A1 (es) * | 2015-08-17 | 2018-06-11 | Japan Tobacco Inc | Compuestos de hidroxitriazina y usos medicos de los mismos |
-
2016
- 2016-08-16 PE PE2018000185A patent/PE20180951A1/es unknown
- 2016-08-16 CN CN201680060597.6A patent/CN108137515B/zh active Active
- 2016-08-16 WO PCT/JP2016/073879 patent/WO2017030115A1/ja active Application Filing
- 2016-08-16 US US15/237,763 patent/US20170057943A1/en not_active Abandoned
- 2016-08-16 KR KR1020187007349A patent/KR20180037270A/ko not_active Application Discontinuation
- 2016-08-16 SG SG11201800698VA patent/SG11201800698VA/en unknown
- 2016-08-16 JP JP2016159454A patent/JP2017039714A/ja not_active Ceased
- 2016-08-16 MX MX2018002044A patent/MX2018002044A/es active IP Right Grant
- 2016-08-16 EP EP22162814.2A patent/EP4046991A1/en active Pending
- 2016-08-16 EP EP16837104.5A patent/EP3339296A4/en not_active Withdrawn
- 2016-08-16 CA CA2992410A patent/CA2992410A1/en active Pending
- 2016-08-16 AU AU2016309337A patent/AU2016309337B2/en active Active
- 2016-08-16 TW TW105126071A patent/TWI704139B/zh active
- 2016-08-16 BR BR112018001809-0A patent/BR112018001809A2/pt not_active Application Discontinuation
- 2016-08-16 AR ARP160102503A patent/AR105711A1/es unknown
-
2018
- 2018-01-24 PH PH12018500181A patent/PH12018500181A1/en unknown
- 2018-02-15 IL IL257559A patent/IL257559B/en unknown
- 2018-02-16 CL CL2018000430A patent/CL2018000430A1/es unknown
- 2018-02-19 ZA ZA2018/01134A patent/ZA201801134B/en unknown
- 2018-03-12 CO CONC2018/0002516A patent/CO2018002516A2/es unknown
-
2020
- 2020-03-03 US US16/807,719 patent/US20210024486A1/en not_active Abandoned
- 2020-09-04 JP JP2020148973A patent/JP2020193235A/ja not_active Ceased
-
2022
- 2022-08-12 JP JP2022128590A patent/JP2022163169A/ja active Pending
-
2023
- 2023-02-24 US US18/114,043 patent/US20240076278A1/en active Pending
- 2023-12-08 JP JP2023207429A patent/JP2024019449A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180037270A (ko) | 2018-04-11 |
| TW201718524A (zh) | 2017-06-01 |
| CN108137515A (zh) | 2018-06-08 |
| WO2017030115A1 (ja) | 2017-02-23 |
| JP2022163169A (ja) | 2022-10-25 |
| BR112018001809A2 (pt) | 2018-09-18 |
| US20170057943A1 (en) | 2017-03-02 |
| US20210024486A1 (en) | 2021-01-28 |
| TWI704139B (zh) | 2020-09-11 |
| PE20180951A1 (es) | 2018-06-11 |
| SG11201800698VA (en) | 2018-03-28 |
| IL257559B (en) | 2021-07-29 |
| CL2018000430A1 (es) | 2018-08-03 |
| CO2018002516A2 (es) | 2018-05-31 |
| JP2024019449A (ja) | 2024-02-09 |
| EP4046991A1 (en) | 2022-08-24 |
| PH12018500181A1 (en) | 2018-07-30 |
| ZA201801134B (en) | 2019-07-31 |
| CN108137515B (zh) | 2021-07-06 |
| US20240076278A1 (en) | 2024-03-07 |
| RU2018109220A3 (es) | 2019-11-15 |
| JP2020193235A (ja) | 2020-12-03 |
| JP2017039714A (ja) | 2017-02-23 |
| IL257559A (en) | 2018-04-30 |
| EP3339296A4 (en) | 2019-01-23 |
| AU2016309337A1 (en) | 2018-02-01 |
| MX2018002044A (es) | 2018-04-13 |
| RU2018109220A (ru) | 2019-09-19 |
| EP3339296A1 (en) | 2018-06-27 |
| AU2016309337B2 (en) | 2021-03-04 |
| CA2992410A1 (en) | 2017-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105711A1 (es) | Compuestos de hidroxitriazina y sus usos farmacéuticos | |
| AR118856A2 (es) | Compuestos terapéuticos | |
| PE20211548A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| CY1121694T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| CY1125051T1 (el) | Συντηγμενη ενωση αναστολεα jak ιμιδαζο-πιπεριδινης | |
| EA201890594A1 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| CL2017001050A1 (es) | Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| AR094311A1 (es) | Derivados de tetrahidroespiro-ciclopropil-pirido[1,2-a]pirazina inhibidores de la integrasa del hiv | |
| EA201591291A1 (ru) | Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| AR111314A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CY1125004T1 (el) | Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας | |
| AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
| AR114420A1 (es) | Derivados de 2,4-diaminoquinazolina y usos médicos de los mismos | |
| UY36124A (es) | Derivados de carboxamida | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| EA201692371A1 (ru) | 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений | |
| NZ764463A (en) | Heterocyclic compound and application thereof in medicine | |
| AR098854A1 (es) | 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas | |
| AR102208A1 (es) | Compuestos de isotiazolo tiazina inhibidores de bace1 | |
| AR099678A1 (es) | Heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis | |
| AR105921A1 (es) | Compuestos terapéuticos para el dolor y síntesis de estos | |
| EA202092107A1 (ru) | Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b |